Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prost...(s evaluated using RECIST (Response Evalu...)

Date:2/25/2009

s evaluated using RECIST (Response Evaluation Criteria in Solid Tumors; an internationally recognized measure of disease progression) in patients with measureable disease showed an overall response rate of 8 percent (one partial response in 13 patients with measureable disease) and a 54 percent disease control rate (six of 13 patients with measureable disease). In comparison, published literature reports overall response rates of 8 to 12 percent in patients treated with docetaxel alone.

These data indicate that picoplatin can be safely administered with full-dose docetaxel. Neutropenia was the main hematologic toxicity. Thrombocytopenia was less severe and less frequent with picoplatin administered in combination with docetaxel compared with picoplatin administered alone.

These findings confirm and extend earlier Phase 2 results presented at the 20th European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland, in October 2008.

"The encouraging PSA response rates, time to PSA progression and radiologic responses rates, combined with the promising safety results observed to date, support further development of picoplatin in combination with docetaxel and prednisone in advanced prostate cancer patients," said Robert De Jager, M.D., chief medical officer of Poniard. "We continue to collect and analyze data from this trial and expect to present updated clinical data, including time to disease progression and overall survival, at medical conferences later this year."

About Picoplatin

Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that it has an improved safety profile relative to existing platinum-based cancer therapies
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation